PPIs Are Not Recommended as Standard Treatment for Acute Pancreatitis
Based on current guidelines, proton pump inhibitors (PPIs) should not be routinely used to treat acute pancreatitis, as established guidelines do not recommend them and the evidence shows no meaningful benefit on mortality or disease severity. 1, 2
Guideline Recommendations
The established guidelines are clear on this matter:
The 1998 UK guidelines explicitly state that various pharmacological treatments, including multiple agents tested in acute pancreatitis, "have no proven value and therefore cannot be recommended" 1. While PPIs are not specifically mentioned in this older guideline, the principle of avoiding unproven therapies is established.
The 2019 WSES guidelines for severe acute pancreatitis do not recommend PPIs as part of the management algorithm 2. The guidelines focus on fluid resuscitation, antibiotics for infected necrosis (not prophylaxis), and supportive care—with no mention of PPIs having a therapeutic role.
Research Evidence: Mixed and Inconclusive
The research literature shows conflicting results, but the highest quality systematic review provides the most reliable answer:
Against PPI Use (Strongest Evidence):
- A 2023 systematic review and meta-analysis of 6 RCTs and 3 cohort studies (28,834 patients) found no evidence for benefit of PPIs in acute pancreatitis 3. This study found:
- No significant difference in 7-day mortality
- No reduction in length of hospital stay
- No decrease in acute respiratory distress syndrome
- The only finding was reduced pseudocyst formation, but this was offset by increased GI bleeding risk
Supporting Studies Show Minimal Clinical Impact:
- A 2015 Japanese study of 10,400 patients with severe acute pancreatitis found PPIs did not affect mortality at 7,14, or 28 days 4
- A 2025 UK Biobank study with animal validation found no meaningful influence on risk of acute, chronic, or pancreatic cancer, with experimental mouse models showing no alteration in pancreatic inflammation 5
Studies Suggesting Benefit Have Significant Limitations:
- Two recent observational studies (2024-2025) suggested reduced mortality and complications with PPI use 6, 7, but these are retrospective cohort studies with high risk of confounding—patients on chronic PPIs likely differ systematically from non-users
- A 2021 multicenter study showed reduced pseudocysts but no mortality benefit 8
Clinical Bottom Line
Do not prescribe PPIs specifically to treat pancreatitis. The theoretical rationale (reducing pancreatic secretion) has not translated into clinically meaningful outcomes in rigorous studies.
When PPIs May Be Appropriate:
- Stress ulcer prophylaxis in ICU patients with severe pancreatitis requiring mechanical ventilation or with coagulopathy (standard ICU indication, not pancreatitis-specific)
- Pre-existing indications (GERD, peptic ulcer disease) that are independent of the pancreatitis diagnosis
Common Pitfall to Avoid:
Many clinicians reflexively prescribe PPIs in pancreatitis, possibly due to:
- Misunderstanding that "pancreatic rest" requires acid suppression (it doesn't)
- Routine stress ulcer prophylaxis protocols applied too broadly
- Confusion between treating pancreatitis versus preventing stress ulcers in critically ill patients
The evidence does not support using PPIs to improve pancreatitis outcomes, and they should only be prescribed when there is a separate, standard indication for their use.